Tablets gastrorezistentny Pantoprazol-Getero are appointed at the following indications:

• Treatment a reflux esophagitis, connected with a gastroesophageal reflux disease (GERD).
• Maintenance of remission of an erosive esophagitis.
• Treatment of morbid hyper secretory conditions, including Zollingera-Ellison's syndrome.

Structure

Active ingredient: pantoprazol;

1 tablet contains 20 mg or 40 mg of a pantoprazol (in the form of a pantoprazol of sodium of sexivihydrat);

Excipients: lactose, hydroxypropyl cellulose, calcium stearate, sodium carbonate anhydrous, sodium lauryl sulfate, cover: a gipromelloza, ferrous oxide yellow (E 172), propylene glycol, the titan dioxide (E 171), methacrylate copolymer (type A), triethyl citrate, polysorbate 80, blackened black (S-1-17823).

Contraindication

Hypersensitivity to active agent, derivatives of benzimidazole and to medicament components.

Route of administration

Pantoprazol-Getero, a gastrorezistentna tablet, swallow entirely, irrespective of meal. To patients who cannot swallow entirely a tablet of 40 mg appoint reception on two tablets of 20 mg. The accompanying reception of antacids does not influence absorption of Pantoprazol-Getero, tablets gastrorezistentny.

to Appoint

Feature of use by

by

for short-term treatment of EE connected with GERD at patients 5 years are more senior.

Drivers

With care.

Overdose

Experience of reception by patients of ultrahigh doses of a pantoprazol (> 240 mg) it is limited. The available data on overdose usually were agreed with the known profile of safety of a pantoprazol. Pantoprazol is not brought from an organism by a hemodialysis. At overdose appoint the symptomatic and supporting treatment.

Side effects

Metabolism and disbolism. Seldom lipidemia and increase in level of lipids (triglycerides, cholesterol), changes of body weight, increase in the KFK level, generalized hypostasis.

from a digestive tract. Infrequently Clostridium difficile-associated diarrhea, nausea, vomiting, an abdominal distension, a constipation, dryness in a mouth, an abdominal pain and discomfort.

by

a concomitant use of an atazanavir or a nelfinavir with inhibitors of a proton pomp as at the same time concentration of an atazanavir or a nelfinavir in blood plasma with the subsequent decrease in their therapeutic effect and development of resistance can decrease.

Storage conditions

to Store

at a temperature not above 25 °C in original packing, out of children's reach.

Expiration date - 2 years.